Search hospitals > Wisconsin > Franklin

Ascension Saint Francis - Reiman Cancer Center

Claim this profile
Franklin, Wisconsin 53132
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
50 reported clinical trials
5 medical researchers
Photo of Ascension Saint Francis - Reiman Cancer Center in FranklinPhoto of Ascension Saint Francis - Reiman Cancer Center in FranklinPhoto of Ascension Saint Francis - Reiman Cancer Center in Franklin

Summary

Ascension Saint Francis - Reiman Cancer Center is a medical facility located in Franklin, Wisconsin. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Breast cancer, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Ascension Saint Francis - Reiman Cancer Center is involved with conducting 50 clinical trials across 172 conditions. There are 5 research doctors associated with this hospital, such as Jonathan S. Treisman, Francis J. Cuevas, Shannon Offerman, and Ranveer Nand.

Area of expertise

1Parotid Gland Cancer
Global Leader
Ascension Saint Francis - Reiman Cancer Center has run 20 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I
2Breast Cancer
Global Leader
Ascension Saint Francis - Reiman Cancer Center has run 14 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
HER2 negative

Top PIs

Clinical Trials running at Ascension Saint Francis - Reiman Cancer Center

Breast Cancer
Lung Cancer
Breast cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Parotid Gland Cancer
Cancer
Plasma Cell Neoplasm
ALK Gene Rearrangement
Prostate Adenocarcinoma
Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Ascension Saint Francis - Reiman Cancer Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security